SG10201708886RA - α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER - Google Patents

α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Info

Publication number
SG10201708886RA
SG10201708886RA SG10201708886RA SG10201708886RA SG10201708886RA SG 10201708886R A SG10201708886R A SG 10201708886RA SG 10201708886R A SG10201708886R A SG 10201708886RA SG 10201708886R A SG10201708886R A SG 10201708886RA SG 10201708886R A SG10201708886R A SG 10201708886RA
Authority
SG
Singapore
Prior art keywords
methods
tumors
compositions
pga
zinc
Prior art date
Application number
SG10201708886RA
Other languages
English (en)
Inventor
Fred Chung Jinhyuk
Original Assignee
Xylonix Ip Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylonix Ip Holdings Pte Ltd filed Critical Xylonix Ip Holdings Pte Ltd
Priority to SG10201708886RA priority Critical patent/SG10201708886RA/en
Priority to PCT/SG2018/050544 priority patent/WO2019088919A1/en
Priority to SG11202003967PA priority patent/SG11202003967PA/en
Priority to US16/760,264 priority patent/US20200254013A1/en
Priority to EP18799880.2A priority patent/EP3703708A1/en
Priority to KR1020207014679A priority patent/KR102725852B1/ko
Priority to CN201880084765.4A priority patent/CN111542328A/zh
Priority to JP2020522999A priority patent/JP7352541B2/ja
Publication of SG10201708886RA publication Critical patent/SG10201708886RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201708886RA 2017-10-30 2017-10-30 α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER SG10201708886RA (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SG10201708886RA SG10201708886RA (en) 2017-10-30 2017-10-30 α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
PCT/SG2018/050544 WO2019088919A1 (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer
SG11202003967PA SG11202003967PA (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer
US16/760,264 US20200254013A1 (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer
EP18799880.2A EP3703708A1 (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer
KR1020207014679A KR102725852B1 (ko) 2017-10-30 2018-10-29 알파-폴리글루탐산-아연을 포함하는 암 치료용 조성물
CN201880084765.4A CN111542328A (zh) 2017-10-30 2018-10-29 用于治疗癌症的包含α-聚谷氨酸-锌的组合物
JP2020522999A JP7352541B2 (ja) 2017-10-30 2018-10-29 がんを処置するためのアルファ－ポリグルタミン酸－亜鉛を含む組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201708886RA SG10201708886RA (en) 2017-10-30 2017-10-30 α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Publications (1)

Publication Number Publication Date
SG10201708886RA true SG10201708886RA (en) 2019-05-30

Family

ID=64184154

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201708886RA SG10201708886RA (en) 2017-10-30 2017-10-30 α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
SG11202003967PA SG11202003967PA (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202003967PA SG11202003967PA (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer

Country Status (7)

Country Link
US (1) US20200254013A1 (https=)
EP (1) EP3703708A1 (https=)
JP (1) JP7352541B2 (https=)
KR (1) KR102725852B1 (https=)
CN (1) CN111542328A (https=)
SG (2) SG10201708886RA (https=)
WO (1) WO2019088919A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022197246A1 (en) 2021-03-18 2022-09-22 Xylonix Pte. Ltd Pharmaceutical polymer conjugates
US11944640B2 (en) 2016-11-01 2024-04-02 Xylonix PTE. LTD. Zinc-[gamma]-PGA compositions and methods for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
CA2395191A1 (en) * 1999-12-23 2001-06-28 Tedman Ehlers Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20020061599A1 (en) * 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
WO2003061598A2 (en) * 2002-01-25 2003-07-31 The University Of Georgia Research Foundation, Inc. Solenopsin a, b and analogs as novel angiogenesis inhibitors
EA016838B1 (ru) * 2005-06-07 2012-07-30 Йельский Университет Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)
JPWO2007043606A1 (ja) * 2005-10-12 2009-04-16 株式会社ジェノラックＢｌ アニオン性ポリアミノ酸／金属複合体からなる抗糖尿病薬剤
JP2010526159A (ja) 2007-04-10 2010-07-29 日東電工株式会社 多機能性ポリグルタミン酸塩薬物担体
US20080279778A1 (en) 2007-05-09 2008-11-13 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
JP2010526812A (ja) * 2007-05-09 2010-08-05 サルトリア・フアーマシユーテイカルズ・エル・エル・シー 炎症性疾患の治療のためのスピロ化合物
US20110117210A1 (en) * 2009-11-17 2011-05-19 Andrey Ugolkov Therapeutic treatment of human cancers using simple salts of zinc
WO2014155142A1 (en) 2013-03-28 2014-10-02 Bbs Nanotechnology Ltd. Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
CN105143242A (zh) 2013-04-26 2015-12-09 日东电工株式会社 大规模制备聚(谷氨酰基-谷氨酸盐)偶联物的方法
SG10201609131YA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11944640B2 (en) 2016-11-01 2024-04-02 Xylonix PTE. LTD. Zinc-[gamma]-PGA compositions and methods for treating cancer
WO2022197246A1 (en) 2021-03-18 2022-09-22 Xylonix Pte. Ltd Pharmaceutical polymer conjugates

Also Published As

Publication number Publication date
SG11202003967PA (en) 2020-05-28
EP3703708A1 (en) 2020-09-09
JP7352541B2 (ja) 2023-09-28
US20200254013A1 (en) 2020-08-13
JP2021501143A (ja) 2021-01-14
KR102725852B1 (ko) 2024-11-05
CN111542328A (zh) 2020-08-14
KR20200080271A (ko) 2020-07-06
WO2019088919A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
MX2024007853A (es) Composicion farmaceutica que comprende un compuesto de quinazolina.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PH12014501560A1 (en) Carbamate compounds and of making and using same
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
EP4140487A8 (en) Combination therapy for treating cancer
WO2016133903A3 (en) Combination therapy for cancer treatment
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
EP4324460A3 (en) Sodium bicarbonate for use in the treatment of gout and related disorders
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
PH12016502355A1 (en) Pharmaceutical composition
PH12020500666A1 (en) Pladienolide compounds and their use
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
PH12020552274A1 (en) Formulations of an axl/mer inhibitor
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法